Hexane

Hexane

SCHEMBL4837985

CC(C)N.CCCCCC.CCOC(C)=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
LMNA P02545 3/20 0.61
HSD17B10 Q99714 1/20 0.61
TP53 P04637 1/20 0.45
OPRM1 P35372 1/20 0.44
FAAH O00519 2/20 0.43
ALOX15 P16050 1/20 0.41
TSHR P16473 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL6217833 0.91 ALDH1A1 (0.74) ALDH1A1LMNAHSD17B10ALOX15TSHR
Hexane SCHEMBL28362891 0.89 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10FAAHTSHR
Hexane SCHEMBL1538450 0.89 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10FAAHTSHR
Hexane SCHEMBL1016091 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL59284 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL547747 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL2701260 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL4897173 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL94510 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15
Hexane SCHEMBL57827 0.89 ALDH1A1 (0.78) ALDH1A1LMNAHSD17B10FAAHALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378428-B2 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-27 US disclosed
US-7094789-B2 5-substituted isoquinoline derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2006-08-22 US disclosed
US-6956033-B2 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-10-18 US disclosed
US-20050222138-A1 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-10-06 US disclosed
EP-1541559-A1 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2005-06-15 EP disclosed
US-20050020623-A1 5-Substituted isoquinoline derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2005-01-27 US disclosed
US-20040077643-A1 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020623-A1 5-Substituted isoquinoline derivatives MYLK, MYLK2, MYL12A ALDH1A1 2534/4885LMNA 178/4885HSD17B10 3170/4885
US-20040077643-A1 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, TRPV1 ALDH1A1 2167/4885LMNA 3762/4885HSD17B10 3830/4885
US-20050222138-A1 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient PARK7, MMP8, CDK7 ALDH1A1 2636/4885LMNA 3014/4885HSD17B10 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.